Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.

Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.